Dr. Davis has significant experience developing and implementing patent portfolio strategies to procure patent protection in the United States and abroad, performing intellectual property due diligence investigations on behalf of investors, financial institutions, and companies in advance of investments in privately held companies, public offerings of securities, strategic alliances, and mergers and acquisitions, and counseling clients on intellectual property risk assessment, post-grant patent proceedings and disputes concerning ownership, validity and infringement of intellectual property rights. For companies developing pharmaceuticals, Dr. Davis develops and implements strategies to maximize patent and regulatory exclusivities for their products.
Exemplary recent representations include:
- Lycera Corporation, a biopharmaceutical company developing medicines for treating autoimmune disease, to develop and implement patent portfolio strategies to procure patent protection for new chemical compounds and therapeutic methods
- Esperion Therapeutics, Inc., a biopharmaceutical company developing medicines for treating cardiovascular disease, to develop and patent portfolio strategies to procure patent protection for new chemical compounds and therapeutic methods
- Diagnostics For All, Inc., a diagnostics company developing medical assay devices, to develop and implement patent portfolio strategies to procure patent protection for new devices for performing medical assays
- BioAmber, a Montreal-based industrial biotechnology company that produces renewable chemicals, in its IPO on the New York Stock Exchange and the NYSE Euronext
Dr. Davis is a member of the American Chemical Society, American Intellectual Property Law Association and Intellectual Property Owners Association.
Prior to joining Goodwin, Dr. Davis was a patent agent at Foley Hoag LLP.